| Typicality: | 0.363 |
| Saliency: | 0.189 |
| at no cost | 3 | manner |
| after efficacy research | 3 | temporal |
| vaccine → be provided to → the public | 6 |
| vaccine → reach → the public | 3 |
| vaccine → be introduced to → the public | 3 |
| negative | neutral | positive |
| 0.082 | 0.598 | 0.321 |
| Raw frequency | 12 |
| Normalized frequency | 0.189 |
| Modifier score | 0.600 |
| Perplexity | 48.633 |